Pharmacological features of factor XII– or factor XI–directed strategies
| Feature . | Antisense oligonucleotides . | Antibodies . | Aptamers . | Small molecules . |
|---|---|---|---|---|
| Delivery | Parenteral | Parenteral | Parenteral | Parenteral or oral |
| Specific | Yes | Yes | Yes | Yes |
| Onset of action | Delayed | Immediate | Immediate | Immediate |
| Offset of action | Delayed | Delayed | Rapid | Rapid |
| Renal clearance | No | No | No | Variable |
| Hepatic metabolism | No | No | No | Variable |
| Potential clinical indications | Chronic | Acute or chronic | Acute or chronic | Acute or chronic |
| Feature . | Antisense oligonucleotides . | Antibodies . | Aptamers . | Small molecules . |
|---|---|---|---|---|
| Delivery | Parenteral | Parenteral | Parenteral | Parenteral or oral |
| Specific | Yes | Yes | Yes | Yes |
| Onset of action | Delayed | Immediate | Immediate | Immediate |
| Offset of action | Delayed | Delayed | Rapid | Rapid |
| Renal clearance | No | No | No | Variable |
| Hepatic metabolism | No | No | No | Variable |
| Potential clinical indications | Chronic | Acute or chronic | Acute or chronic | Acute or chronic |